Dr. Kenneth E. Rosenzweig, MD

Dr. Rosenzweig practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Rosenzweig's NPI, 1063482271, was assigned on January 23, 2006. Dr. Rosenzweig graduated from Yale School of Medicine in 1992. Dr. Rosenzweig holds New York license 206749.

Dr. Rosenzweig's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Rosenzweig also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Rosenzweig's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Rosenzweig to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenzweig practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rosenzweig's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rosenzweig is board certified in radiation oncology by the American Board of Radiology. Dr. Rosenzweig is licensed in New York.

Dmand AI lists bone cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Rosenzweig treats.

CMS data shows 582 Medicare services from Dr. Rosenzweig across 12 procedure codes in 2024, for 119 Medicare patients. Medicare paid $63,260 for them.

CMS counts 119 Medicare patients who saw Dr. Rosenzweig in 2024. The largest group is 75 to 84, with 59 patients. 75% of them have cancer, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenzweig's median patient age at 75, with 47% women.

In 2017, Dr. Rosenzweig wrote 13 Medicare Part D claims. They cover 1 drug, with $155 in total drug cost.

Dr. Rosenzweig accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenzweig as offering telehealth.

Dmand AI links 178 papers to Dr. Rosenzweig, published from 2005 to 2025. 2018 was the busiest year, with 12. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiotherapy Dosage. Dr. Rosenzweig has published most often in Int J Radiat Oncol Biol Phys. Dr. Rosenzweig's most frequent co-authors are Andreas Rimner, MD, Abraham Jing-Ching Wu, MD and Valerie W. Rusch, MD.

Dmand AI links Dr. Rosenzweig to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic.

CMS Open Payments shows 22 general payments to Dr. Rosenzweig from 4 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 81% of the total. Varian Medical Systems, Inc. paid the most, $1,513.

Dr. Rosenzweig serves on Definitive and Adjuvant Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Guideline Panel American Society for Radiation Oncology.

Dr. Rosenzweig graduated from Yale School of Medicine in 1992.

Dr. Rosenzweig is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.